Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haitrombopag ethanolamine
- Development stage
- Unknown
- Lead developer
- Jiangsu Hengrui Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Haitrombopag ethanolamine is a small-molecule, non-peptide thrombopoietin receptor (TPO-R) agonist developed by Jiangsu Hengrui Pharmaceuticals. It acts as an allosteric agonist by binding to the transmembrane domain of the TPO receptor (also known as MPL), which triggers intracellular signaling pathways, including the JAK/STAT and MAPK pathways. This stimulation promotes the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, leading to increased platelet production. Haitrombopag was approved by the China National Medical Products Administration (NMPA) in 2021 for the treatment of chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to other treatments, and it is also indicated for severe aplastic anemia (SAA).
- Brand names
- Hengqu
- Other names
- haitrombopaghaitrombopag olamine
02
Targets
TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on haitrombopag ethanolamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haitrombopag ethanolamine.